EA
BIIB icon

Emerald Acquisition’s Biogen BIIB Stock Holding History

Emerald Acquisition’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$93.8M Buy
299,602
+46,198
+18% +$13.7M 0.18% 128
2016
Q2 		$61.3M Buy
+253,404
New +$66.8M 0.11% 215

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Emerald Acquisition's BIIB Position: Q3 2016 in Review

Emerald Acquisition increased its Biogen (BIIB) stake by 18% in Q3 2016, buying an estimated $13.7M and bringing the position to 299,602 shares worth $93.8M. The position accounts for 0.18% of the portfolio, ranked #128.

Emerald Acquisition first reported a position in BIIB in Q2 2016 and has held it in 2 quarters since. 1,012 funds tracked by Wall St. Rank hold BIIB as of Q3 2016.

  • Emerald Acquisition held 299,602 shares of Biogen worth $93.8M as of Q3 2016.
  • Emerald Acquisition bought 46,198 Biogen shares in Q3 2016, an estimated $13.7M.
  • Biogen made up 0.18% of Emerald Acquisition's portfolio in Q3 2016, its #128 holding.
  • Emerald Acquisition first reported a position in Biogen in Q2 2016 and has held it in 2 quarters since.
  • 1,012 funds tracked by Wall St. Rank held Biogen as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.